Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica Ailani

Showing results (61-70 of 114) with videos related to

Pageof 12
Sort By:
Cephalalgia : an International Journal of Headache|June 12, 2016
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial programRichard B Lipton, Noah L Rosen, Jessica Ailani, et al.
The Journal of Headache and Pain|July 26, 2019
Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trialsLi Shen Loo, Jessica Ailani, Jack Schim, et al.
The Lancet. Neurology|August 22, 2020
Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trialPeter J Goadsby, David W Dodick, Jessica Ailani, et al.
Headache|January 25, 2022
Does "wearing off" of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trialsJessica Ailani, Dulanji K Kuruppu, Mallikarjuna Rettiganti, et al.
The Journal of Headache and Pain|January 3, 2025
Reduction of pain and functional disability over time in patients treated with zavegepant: a post-hoc analysis of the BHV3500-301 phase 3 randomized controlled trialLauren Powell, Fiona O'Sullivan, Pramoda Jayasinghe, et al.
Headache|November 12, 2019
Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE StudiesHolland C Detke, Brian A Millen, Qi Zhang, et al.
Headache|September 24, 2019
Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) StudyRichard B Lipton, Susan Hutchinson, Jessica Ailani, et al.
Headache|July 3, 2024
Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacksRichard B Lipton, Jessica Ailani, Kathleen Mullin, et al.
Mayo Clinic Proceedings|April 6, 2020
Characterization of Acute Prescription Migraine Medication Use: Results From the CaMEO StudySusan Hutchinson, Richard B Lipton, Jessica Ailani, et al.
The New England Journal of Medicine|August 18, 2021
Atogepant for the Preventive Treatment of MigraineJessica Ailani, Richard B Lipton, Peter J Goadsby, et al.
Pageof 12

Showing results (61-70 of 114) with videos related to

Sort By:
Pageof 12
Cephalalgia : an International Journal of Headache|June 12, 2016
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial programRichard B Lipton, Noah L Rosen, Jessica Ailani, et al.
The Journal of Headache and Pain|July 26, 2019
Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trialsLi Shen Loo, Jessica Ailani, Jack Schim, et al.
The Lancet. Neurology|August 22, 2020
Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trialPeter J Goadsby, David W Dodick, Jessica Ailani, et al.
Headache|January 25, 2022
Does "wearing off" of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trialsJessica Ailani, Dulanji K Kuruppu, Mallikarjuna Rettiganti, et al.
The Journal of Headache and Pain|January 3, 2025
Reduction of pain and functional disability over time in patients treated with zavegepant: a post-hoc analysis of the BHV3500-301 phase 3 randomized controlled trialLauren Powell, Fiona O'Sullivan, Pramoda Jayasinghe, et al.
Headache|November 12, 2019
Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE StudiesHolland C Detke, Brian A Millen, Qi Zhang, et al.
Headache|September 24, 2019
Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) StudyRichard B Lipton, Susan Hutchinson, Jessica Ailani, et al.
Headache|July 3, 2024
Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacksRichard B Lipton, Jessica Ailani, Kathleen Mullin, et al.
Mayo Clinic Proceedings|April 6, 2020
Characterization of Acute Prescription Migraine Medication Use: Results From the CaMEO StudySusan Hutchinson, Richard B Lipton, Jessica Ailani, et al.
The New England Journal of Medicine|August 18, 2021
Atogepant for the Preventive Treatment of MigraineJessica Ailani, Richard B Lipton, Peter J Goadsby, et al.
Pageof 12